Ambrisentan for in pediatric pulmonary arterial hypertension: a cost-utility analysis.

Our economic evaluation shows that ambrisentan is not cost-effective regarding sildenafil to treat pediatric patients with Pulmonary arterial hypertension in Colombia. Our study provides evidence that should be used by decision-makers to improve clinical practice guidelines. This article is protected by copyright. All rights reserved.